Calcium in the regulation of osteoclast formation

钙对破骨细胞形成的调节

基本信息

  • 批准号:
    7262485
  • 负责人:
  • 金额:
    $ 44.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-08-01 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

CD38 (ADP-ribosyl cyclase) catalyses the cyclization of NAD+ to cyclic ADP-ribose (cADPr), a second messenger that releases Ca2+ from ryanodine receptor-gated Ca2+ stores. During the current funding period, we have made several key observations. Firstly, we showed that CD38 is expressed in abundance in the osteoclast, and its stimulation by an activating antibody triggers Ca2+ release via ryanodine receptors resulting resorption inhibition. Second, we found that the CD38-/- mouse displays profound osteoporosis characterized by excessive bone loss due to increased osteoclast formation and resorptive function. Finally, to study the topological requirements for NAD+-induced Ca2+ signaling, we made several mutated CD38 constructs that did not localize the plasma membrane. We demonstrated that microsomal membrane, rather that the plasma membrane CD38 is necessary for NAD+-induced Ca2+ release in NIH3T3 cells. Our hypothesis is that CD38 negatively regulates osteoclast formation and function by acting as an intracellular ?NAD? receptor? that couples intermediary metabolism for Ca2+ signaling. We will explore this hypothesis in two specific aims. Specific aim 1 will focus on the function of CD38 as a negative regulation of osteoclast formation. We will further characterize the bone phenotype of CD38-/- mice using densitometry, 3-dimensional pQCT imaging, histomorphometry, and biomechanical testing. We will also examine ex vivo osteoclast formation in CD38-/- mice, and more importantly, determine whether the cellular phenotype (a) is mediated via supporting osteoblasts, and (b) can be rescued by adenoviral CD38 transfer. Specific aim 2 will investigate whether CD38, as a putative NAD+ regulator, negatively regulates the resorptive function of mature osteoclasts. We will first examine the localization and function of endogenous and recombinant full-length CD38 and each CD38 mutant in the osteoclast by confocal microscopy, immunoblotting and cyclase assays. We will next characterize NAD+-induced cytosolic Ca2+ responses in osteoclasts infected with full length CD38 or its mutated constructed. We will also investigated whether CD38 inhibits osteoclastic bone resorption in the pit assay by sensitizing both microsomal and plasma membrane ryanodine receptors. Finally, we will determine whether CD38 over-expression in transgenic mice results in an osteopetrotic phenotype and dysfunctional osteoclasts.
CD 38(ADP-核糖基环化酶)催化NAD+环化为环状ADP-核糖(cADPr),cADPr是从兰尼碱受体门控的Ca 2+储存中释放Ca 2+的第二信使。在本报告所述期间,我们提出了几项重要意见。首先,我们表明CD 38在破骨细胞中大量表达,激活抗体对其的刺激通过兰尼碱受体触发Ca 2+释放,从而抑制吸收。其次,我们发现CD 38-/-小鼠表现出严重的骨质疏松症,其特征在于由于破骨细胞形成和吸收功能增加而导致的过度骨丢失。最后,为了研究NAD+诱导的Ca2+信号传导的拓扑要求,我们制备了几种不定位于质膜的突变的CD38构建体。我们证明,微粒体膜,而不是质膜CD 38是必需的NAD+诱导的Ca 2+释放在NIH3T3细胞。我们的假设是,CD38负调控破骨细胞的形成和功能,作为细胞内?NAD?受体?连接中间代谢和Ca2+信号传导。我们将在两个具体目标中探讨这一假设。具体目标1将集中于CD38作为破骨细胞形成的负调节的功能。我们将使用密度测定、三维pQCT成像、组织形态测定和生物力学测试进一步表征CD 38-/-小鼠的骨表型。我们还将检查CD 38-/-小鼠中的体外破骨细胞形成,更重要的是,确定细胞表型(a)是否通过支持成骨细胞介导,以及(B)是否可以通过腺病毒CD 38转移来拯救。具体目标2将研究CD38作为一种假定的NAD+调节剂是否负调节成熟破骨细胞的吸收功能。我们将首先研究的本地化和功能的内源性和重组全长CD38和每个CD38突变体的破骨细胞共聚焦显微镜,免疫印迹和环化酶测定。我们接下来将描述用全长CD38或其突变构建体感染的破骨细胞中NAD+诱导的胞浆Ca 2+反应。我们还将研究CD38是否通过致敏微粒体和质膜ryanodine受体来抑制骨陷窝试验中的骨吸收。最后,我们将确定转基因小鼠中CD38的过度表达是否会导致骨硬化表型和破骨细胞功能障碍。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mone Zaidi其他文献

Mone Zaidi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mone Zaidi', 18)}}的其他基金

Exploring The Posterior Pituitary-Bone Connection
探索垂体后叶与骨的连接
  • 批准号:
    8489237
  • 财政年份:
    2011
  • 资助金额:
    $ 44.99万
  • 项目类别:
Exploring The Posterior Pituitary-Bone Connection
探索垂体后叶与骨的连接
  • 批准号:
    8165106
  • 财政年份:
    2011
  • 资助金额:
    $ 44.99万
  • 项目类别:
4th NY Skeletal Biology and Medicine Conference
第四届纽约骨骼生物学和医学会议
  • 批准号:
    8128138
  • 财政年份:
    2011
  • 资助金额:
    $ 44.99万
  • 项目类别:
Exploring The Posterior Pituitary-Bone Connection
探索垂体后叶与骨的连接
  • 批准号:
    8316115
  • 财政年份:
    2011
  • 资助金额:
    $ 44.99万
  • 项目类别:
Exploring The Posterior Pituitary-Bone Connection
探索垂体后叶与骨的连接
  • 批准号:
    8686698
  • 财政年份:
    2011
  • 资助金额:
    $ 44.99万
  • 项目类别:
Exploring The Posterior Pituitary-Bone Connection
探索垂体后叶与骨的连接
  • 批准号:
    9051298
  • 财政年份:
    2011
  • 资助金额:
    $ 44.99万
  • 项目类别:
Role of FSH in Osreoclast Formation and Function
FSH 在破骨细胞形成和功能中的作用
  • 批准号:
    7914737
  • 财政年份:
    2009
  • 资助金额:
    $ 44.99万
  • 项目类别:
3rd Skeletal Biology and Medicine Conference
第三届骨骼生物学与医学会议
  • 批准号:
    7674393
  • 财政年份:
    2009
  • 资助金额:
    $ 44.99万
  • 项目类别:
Skeletal Biology and Medicine Conference
骨骼生物学和医学会议
  • 批准号:
    7277874
  • 财政年份:
    2007
  • 资助金额:
    $ 44.99万
  • 项目类别:
Skeletal Development and Remodeling in Health, Disease and Aging
健康、疾病和衰老中的骨骼发育和重塑
  • 批准号:
    7001960
  • 财政年份:
    2005
  • 资助金额:
    $ 44.99万
  • 项目类别:

相似海外基金

Function of extracellular ADP-ribosyl cyclase BST-1/CD157 in the intestine
细胞外 ADP-核糖基环化酶 BST-1/CD157 在肠道中的功能
  • 批准号:
    26460499
  • 财政年份:
    2014
  • 资助金额:
    $ 44.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of ADP ribosyl cyclase in pathogenesis of preeclampsia
ADP核糖基环化酶在先兆子痫发病机制中的作用
  • 批准号:
    24659409
  • 财政年份:
    2012
  • 资助金额:
    $ 44.99万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
ADP-ribosyl cyclase coupled with dopamine receptors : Application to Parkinson's disease
ADP-核糖基环化酶与多巴胺受体偶联:在帕金森病中的应用
  • 批准号:
    15300124
  • 财政年份:
    2003
  • 资助金额:
    $ 44.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
ASSOCIATION OF ADP RIBOSYL CYCLASE W/ FLUORESCENT SUBSTRATE
ADP 核糖基环化酶与荧光底物的关联
  • 批准号:
    6645967
  • 财政年份:
    2002
  • 资助金额:
    $ 44.99万
  • 项目类别:
STRUCTURE-FUNCTION OF ADP-RIBOSYL CYCLASE AND HOMOLOGS
ADP-核糖基环化酶及其同系物的结构-功能
  • 批准号:
    6030325
  • 财政年份:
    2000
  • 资助金额:
    $ 44.99万
  • 项目类别:
Molecular Characterization of ADP-ribosyl Cyclase Coupled with Receptors
与受体偶联的 ADP-核糖基环化酶的分子表征
  • 批准号:
    12480228
  • 财政年份:
    2000
  • 资助金额:
    $ 44.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
STRUCTURE-FUNCTION OF ADP-RIBOSYL CYCLASE AND HOMOLOGS
ADP-核糖基环化酶及其同系物的结构-功能
  • 批准号:
    6498704
  • 财政年份:
    2000
  • 资助金额:
    $ 44.99万
  • 项目类别:
ASSOCIATION OF ADP RIBOSYL CYCLASE W/ FLUORESCENT SUBSTRATE
ADP 核糖基环化酶与荧光底物的关联
  • 批准号:
    6348034
  • 财政年份:
    2000
  • 资助金额:
    $ 44.99万
  • 项目类别:
STRUCTURE-FUNCTION OF ADP-RIBOSYL CYCLASE AND HOMOLOGS
ADP-核糖基环化酶及其同系物的结构-功能
  • 批准号:
    6351317
  • 财政年份:
    2000
  • 资助金额:
    $ 44.99万
  • 项目类别:
Does streptococcal ADP ribosyl cyclase/cADPR hydrolase evokeIgdassswitch?
链球菌 ADP 核糖基环化酶/cADPR 水解酶是否会引起 Igdass 开关?
  • 批准号:
    12670251
  • 财政年份:
    2000
  • 资助金额:
    $ 44.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了